Compare VRAX & SOBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAX | SOBR |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 3.3M |
| IPO Year | 2021 | 2008 |
| Metric | VRAX | SOBR |
|---|---|---|
| Price | $0.20 | $0.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 189.1K | 128.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,736.00 |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.19 | $0.46 |
| 52 Week High | $1.43 | $7.70 |
| Indicator | VRAX | SOBR |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 46.72 |
| Support Level | $0.20 | $0.67 |
| Resistance Level | $0.25 | $2.19 |
| Average True Range (ATR) | 0.02 | 0.08 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 13.74 | 85.52 |
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.